Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVAM Chemotherapy for Refractory or Relapsed DLBCL
NCT03383406Phase 2Enrolling by invitation
- Sponsor
- Asan Medical Center
- Start
- Dec 2016
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of ifosfamide, etoposide, cytarabine, methotrexate in diffuse large B-cell lymphoma (DLBCL), sponsored by Asan Medical Center. Started Dec 2016; status: enrolling by invitation.
02
Drugs
ifosfamideetoposidecytarabinemethotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03383406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383406.